Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led their commercial launch and sales. He has spearheaded license, research, technology transfer, investment, and sales and marketing agreements with Fortune 500 companies such as Eastman Kodak, Abbott Diagnostics, Johnson & Johnson, IBM, and Ping An. Mr. Cohen has also been a leading advocate in Annapolis, MD, and on Capitol Hill on behalf of small and emerging biotechnology and diagnostics companies. Before founding our company, Mr. Cohen was patent and general counsel for Ventana Medical Systems Inc. and Oncor Inc. He has a Master of Science Degree in Biotechnology from Johns Hopkins University and a law degree from American University.
Dr. Zhou has over 20 years of healthcare and biotech industry experience. He began his academic career as an associate professor at Sichuan University in China and conducted extensive research at the University of Iowa. He transitioned to industrial R&D in 2005, leading major pharmaceutical projects and managing multiple clinical labs. Dr. Zhou previously co-founded Firefox Pharmaceuticals and Fairfax Medical Consulting. He received his Ph.D. in Biology from Sichuan University.
Mr. Bergman has served as our Interim Chief Financial Officer since December 2025 and will be appointed as our Chief Financial Officer effective automatically on the effective date of the registration statement of which this prospectus forms a part. Mr. Bergman’s expertise includes corporate financial management, mergers and acquisitions, corporate reorganizations, cost reduction and avoidance, financial analysis and reporting, IPO management, contract negotiations, ISO 9000 Quality Systems and SEC reporting and compliance. Prior to joining us, he served as the chief financial officer of Plethy, Inc., a private musculoskeletal med-tech company, from December 2024 to December 2025. From January 2021 to December 2024, he served as the chief financial officer of Smart for Life, Inc., a publicly traded company engaged in the sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. He previously served as chief financial officer and vice president finance at Bright Mountain Media, Inc. from June 2019 to December 2020. Prior to that, he served as vice president finance at Greenlane Holdings, Inc., from December 2018 to May 2019. He previously served as controller for Woodfield Distribution from October 2013 to February 2018 and as vice president finance at Latitude Solutions from May 2011 to March 2013. Mr. Bergman commenced his career in 2000 with Deloitte as a senior auditor and subsequently as audit manager at Mallah Furman, P.A. and as senior auditor at Weinberg & Company, P.A. In addition, Mr. Bergman has been an Adjunct Professor of Accounting at Florida Atlantic University and Millennia Atlantic University. Mr. Bergman received his Master’s Degree in Accounting from University of Miami.
Dr. Lebowitz has served as Chief Scientific Officer since January 2020, previously Director of Research & Development from 2009-2012. Concurrently, he is CSO at Athanor Biosciences. He has over 30 years of research experience, including 22 years in industry and over 18 years in research management. Dr. Lebowitz has been directly involved in launching six laboratory-developed tests and establishing two CLIA-certified labs. He holds a Ph.D. from Johns Hopkins University School of Medicine, completed a fellowship in immunology there, and is an adjunct faculty member at Johns Hopkins University and the University of Maryland, Baltimore County.
Mr. Baker has extensive experience in clinical research, operations, technical sales, marketing, and business development within oncology laboratory services. Prior to joining 20/20, he held executive positions at Roche Diagnostics, Roche Clinical Labs, and SGS Life Sciences. Mr. Baker earned his BS in Biology from Loyola University.
Mr. Lees rejoined 20/20 as Director of Sales in 2023 after exceptional performance at Software AG. He previously served as Sales Manager at 20/20 and is recognized for driving significant revenue growth. Mr. Lees holds a degree in Biochemistry from Christopher Newport University.
